What question did this study set out to answer?

The aim is to identify gut microbiome-derived prolyl peptidases that can degrade immunogenic gliadin peptides associated with celiac disease.

May 31, 2026Microbiology SpectrumOpen Access

Harnessing gut microbiome enzymes: Segatella copri and Stenotrophomonas maltophilia prolyl peptidases degrade gliadin peptides and improve epithelial barrier function in a celiac disease model

View Full Paper

Ask AI

Bookmark

The aim is to identify gut microbiome-derived prolyl peptidases that can degrade immunogenic gliadin peptides associated with celiac disease.
Conducted metagenomic mining and structure-based screening to identify enzymes PSP692 and PSP464.
Characterized enzymatic activity under various pH conditions and assessed effects on CaCo-2 cell line in functional assays.
PSP692 efficiently degrades the 33-mer gliadin peptide at pH 6, and PSP464 targets the 11-mer at pH 4.
Degradation by these enzymes significantly restored tight junction proteins (ZO-1 and occludin) and reduced IL-6 secretion, enhancing barrier integrity.

No takes yet. Share an insight, caveat, or question.

Randomized trial demonstrates improved epithelial barrier function in celiac disease model using gut-derived enzymes, suggesting new therapies.

Karmarkar et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates improved epithelial barrier function in celiac disease model using gut-derived enzymes, suggesting new therapies.